Special Issue "Pediatric Asthma"

A special issue of Children (ISSN 2227-9067). This special issue belongs to the section "Integrative Pediatrics".

Deadline for manuscript submissions: 30 September 2020.

Special Issue Editor

Dr. Giorgio Ciprandi

Guest Editor
Allergy Clinic, Casa di Cura Villa Montallegro, Genoa, Italy.
Interests: Allergy

Special Issue Information

Dear Colleagues,

Pediatric asthma is a clinically relevant issue and deserves adequate attention. It is well known that asthma is characterized by airway inflammation and bronchial hyperresponsiveness. New evidence is continuously reported in literature, but most of the research papers concern data deriving from big data. Thus, there is the need to implement studies conducted in real life. Moreover, there is the need to have simple tools to measure asthma control and to evaluate emotional aspects in children and adolescents with asthma. Therefore, we invite original research (both clinical and translational) and review articles addressing these controversies. Manuscripts addressing challenges with optimal targets for new theraputical strategies and asthma work-up innovation will be considered. We also invite epidemiological studies and interesting case reports followed by a discussion that includes clinical pearls.

Dr. Giorgio Ciprandi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Asthma
  • Children
  • Adolescents
  • Diagnosis
  • Management
  • Control
  • Emotional aspects
  • Treatment

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

Open AccessCommunication
Pragmatic Markers in the Management of Asthma: A Real-World-Based Approach
Children 2020, 7(5), 48; https://doi.org/10.3390/children7050048 - 18 May 2020
Abstract
Bronchial hyperreactivity, reversible airflow limitation and chronic airway inflammation characterize asthma pathophysiology. Personalized medicine, i.e., a tailored management approach, is appropriate for asthma management and is based on the identification of peculiar phenotypes and endotypes. Biomarkers are necessary for defining phenotypes and endotypes. [...] Read more.
Bronchial hyperreactivity, reversible airflow limitation and chronic airway inflammation characterize asthma pathophysiology. Personalized medicine, i.e., a tailored management approach, is appropriate for asthma management and is based on the identification of peculiar phenotypes and endotypes. Biomarkers are necessary for defining phenotypes and endotypes. Several biomarkers have been described in asthma, but most of them are experimental and/or not commonly available. The current paper will, therefore, present pragmatic biomarkers useful for asthma management that are available in daily clinical practice. In this regard, eosinophil assessment and serum allergen-specific IgE assay are the most reliable biomarkers. Lung function, mainly concerning forced expiratory flow at 25-755 of vital capacity (FEF25-75), and nasal cytology may be envisaged as ancillary biomarkers in asthma management. In conclusion, biomarkers have clinical relevance in asthma concerning both the endotype definition and the personalization of the therapy. Full article
(This article belongs to the Special Issue Pediatric Asthma)
Show Figures

Figure 1

Open AccessArticle
The Measurement of Asthma and Allergic Rhinitis Control in Children and Adolescents
Children 2020, 7(5), 43; https://doi.org/10.3390/children7050043 - 07 May 2020
Abstract
Asthma and allergic rhinitis (AR) are frequently associated. The objective of the treatment of asthma and AR should be the control of symptoms and disease progression. Therefore, the combined measurement of disease control is desirable. In this regard, a questionnaire able to together [...] Read more.
Asthma and allergic rhinitis (AR) are frequently associated. The objective of the treatment of asthma and AR should be the control of symptoms and disease progression. Therefore, the combined measurement of disease control is desirable. In this regard, a questionnaire able to together assess asthma and AR control has been validated: the CARAT (Control of Allergic Rhinitis and Asthma Test). A further pediatric version (CARATkids) has been generated. The current real-world study used different disease control measures in children and adolescents with asthma and rhinitis. A total of 138 children and adolescents were recruited at three allergy centers. CARAT, CARATkids, ACT (Asthma Control Test), cACT (children ACT), GINA (Global Initiative for Asthma) disease control classification, VAS (Visual Analog Scale) for asthma and nasal symptoms, and lung function were used in all subjects. There was a predominance of males (67.4%) and asthma was well-controlled (according to GINA classification) in about half the subjects. In children, the median CARAT and cACT values were 5 and 22 respectively. In adolescents, the median CARAT and ACT values were 23 for both tests. There were significant differences between CARAT and ACT (p = 0.035) as well as between CARATkids and cACT (p = 0.0001). However, the tests’ outcomes were different as assessed in different domains. CARAT and CARATkids are disease-control measurements that give additional information to other tests, therefore, these different questionnaires to measure disease control complement each other. Full article
(This article belongs to the Special Issue Pediatric Asthma)
Show Figures

Figure 1

Review

Jump to: Research

Open AccessReview
Allergen Immunotherapy in Pediatric Asthma: A Pragmatic Point of View
Children 2020, 7(6), 58; https://doi.org/10.3390/children7060058 - 08 Jun 2020
Abstract
To date, the only disease-modifying treatment strategy for allergic rhinitis and asthma is allergen immunotherapy (AIT). There is evidence that AIT improves allergic rhinitis and asthma, such as reducing symptom severity and medication use and improving of quality of life, with a long-lasting [...] Read more.
To date, the only disease-modifying treatment strategy for allergic rhinitis and asthma is allergen immunotherapy (AIT). There is evidence that AIT improves allergic rhinitis and asthma, such as reducing symptom severity and medication use and improving of quality of life, with a long-lasting effect after the end of the course. The recent clinical trials evidenced AIT effectiveness and safety in allergic asthma. Consequently, the current version of the GINA (Global Initiative for Asthma) guidelines recommend AIT as an add-on therapy for asthma. There is also evidence that AIT may exert preventive activity on the possible progression from allergic rhinitis to asthma in children and the onset of new sensitizations. The present review provides a pragmatic summary of the clinical indications of AIT in pediatric asthma, including the immunological mechanisms, the predictive biomarkers, and the safety issues in clinical practice. Full article
(This article belongs to the Special Issue Pediatric Asthma)
Back to TopTop